DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Stelo, a new over-the-counter glucose biosensor designed for adults with prediabetes and Type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

DexCom Inc.

In a report released yesterday, Shagun Singh Chadha from RBC Capital maintained a Buy rating on Dexcom, with a price target of $85.00. Singh Chadha...

RBC Capital Keeps Their Buy Rating on Dexcom (DXCM)

In a report released on July 6, Joanne Wuensch from Citi reiterated a Buy rating on Dexcom, with a price target of $84.00. The company’s shares clo...

Dexcom (DXCM) Receives a Buy from Citi

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Dexcom (DXCM) and Vera Therapeutics (VERA) with bull...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	DXCM	$73.37	+2.56%	5.00M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	DXCM	$73.37	+2.6%	5.00M
3
4
5
6

DXCM

DXCM

Get DexCom Inc. Data in Excel

Get DexCom Inc. Data in Excel